FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an isolated anti-PD-L1 antibody or its antigen-binding fragment. Polynucleotide and combination of isolated polynucleotides encoding the specified antibody; and expression vector containing the specified polynucleotide; a host cell containing the specified vector; a conjugate and a pharmaceutical composition containing the specified antibody are also disclosed. A method for the production of the specified anti-PD-L1 antibody; a method for enhancing a function of T-cells, a method for the treatment of T-cell disfunction, using the specified antibody; and the use of the specified antibody for the treatment or prevention of PD-L1-related cancer are disclosed.
EFFECT: invention allows for effective treatment of diseases associated with PD-L1 factor.
29 cl, 5 dwg, 11 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
